TG Ther­a­peu­tics signs $645M deal to kick-start in­ter­na­tion­al launch of MS an­ti­body 

TG Ther­a­peu­tics is look­ing to ex­pand ac­cess to its CD20 an­ti­body Briumvi out­side North Amer­i­ca and has an­nounced a part­ner­ship with the Eu­ro­pean phar­ma com­pa­ny Neu­rax­pharm.

The deal is for $140 mil­lion in cash up­front, plus an­oth­er $12.5 mil­lion once the drug, ap­proved in the US and EU for adults with re­laps­ing forms of mul­ti­ple scle­ro­sis, is launched in the first EU mem­ber coun­try, ac­cord­ing to a press re­lease Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.